Monjuvi
About Tafasitamab
Tafasitamab is a prescribed medicine for the treatment of Lenalidomide and the CD19-directed cytolytic antibody Tafasitamab is recommended for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that has relapsed or become resistant, including DLBCL resulting from low-grade lymphoma, and who are not candidates for autologous stem cell transplant (ASCT).
Based on the total response rate, this indication is granted under rapid approval. Continued clearance for this indication might be reliant on confirmatory trials demonstrating and describing the clinical benefit.
Strength
200 mg; single dose vial
Recommended Dosage
The recommended dosage of Tafasitamab is 12 mg/kg as an intravenous infusion.
Important: If patients experience any adverse reactions from the Tafasitamab treatment, it is necessary to consult the treating doctor.
Warnings & Precautions
- Throughout the infusion, it is necessary to administer the patients depending on the severity, stop or pause the infusion (Infusion-related reaction).
- The treating doctor should track full blood counts (Myelosuppression). Modify dosage and support growth factors to manage. Depending on the severity, withhold or withdraw Tafasitamab treatment.
- Bacteria, fungi, or viruses can be caused during and after Tafasitamab. Check for infections in patients (Infections).
- Tafasitamab treatment may be harmful to a fetus. The treating doctor must inform women who are sexually active about the potential danger to an unborn child and encourage them to utilize reliable contraception (Embryo-Fetal Toxicity).
Common Tafasitamab Side Effects
- Neutropenia
- Fatigue
- Anemia
- Diarrhea
- Thrombocytopenia
- Cough
- Pyrexia
- Peripheral edema
- Respiratory tract infection
- Reduced appetite
Storage and Handling
In a carton, each 200 mg vial is separately packed.
Keep chilled at 2 to 8 °C in the original carton to avoid light exposure. Do not tremble.
Avoid freezing.
We follow a four-step process to procure the medicines:
- Enquiry about the medicines: You submit a request for information about the medications you require using our portal, and we process your data. Within 24 hours, a member of our Named Access Program Support will get in touch with you and provide you with all the assistance you need.
- Verification Process: As we assist patients in finding medications that are not yet approved and readily available in their home countries, Sansfro must confirm the availability and approval of the medicines they need. We also check the patient’s prescription and medical information.
- Sourcing the Medicine: After the verification process has been completed, our staff will contact our vast network of suppliers to find your medicine. Following the process, our team gets the best rates of the medicines for you and ensures processing.
- Safe Delivery: We will set up the consignment’s safe delivery after the final quote is approved. Additionally, our logistics experts can help you track your consignment. The Named Access Program industry has a large number of unauthorized channels. To provide the medications safely and legally, we do so by adhering to the Standard Operating Procedures.
When importing medication, we will need the following documents from the patient:
- A valid prescription copy.
- An identity proof document.
- Details of the attending healthcare professional.
- A current address.
Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.
No news found.
About Sansfro
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...FAQ'S
What kinds of cancer does Monjuvi treat?
A: To treat people with diffuse large B-cell lymphoma (DLBCL), a kind of non-Hodgkin lymphoma, which has relapsed or is refractory, Monjuvi is combined with lenalidomide.
How does Monjuvi function?
A specific protein called CD19 that is present on the surface of malignant B-cells is the target and the binding site for the drug Monjuvi. Monjuvi aids the immune system in identifying and combating cancer cells, preventing their proliferation, by attaching to CD19.
How to administer Tafasitamab?
Monjuvi is administered by a healthcare practitioner by intravenous (IV) infusion. The first infusion is often administered over many hours, with successive infusions being shorter depending on the patient’s tolerance.
What is the recommended dosage of Tafasitamab?
Monjuvi of Tafasitamab dose is determined by factors such as the patient’s weight and medical condition. It is typically used in conjunction with lenalidomide. A qualified healthcare professional should establish a dosage schedule for the patient.
What are the common Monjuvi side effects?
Fatigue, diarrhea, fever, cough, nausea, headache, and low levels of particular blood cells are all common adverse effects of Monjuvi. More significant side effects are possible, therefore patients should discuss potential concerns with their doctor.
Is Monjuvi appropriate for all DLBCL patients?
Monjuvi or Tafasitamab is indicated for patients with relapsed or refractory DLBCL who are not candidates for autologous stem cell transplant and have not responded to earlier treatment choices.
What should I discuss with my doctor before beginning Tafasitamab treatment?
It is necessary to discuss the medical history, current medicines, allergies, and any other health issues with the treating doctor before beginning Monjuvi treatment. This will assist the patient in determining whether Monjuvi is a safe and acceptable treatment for the patient.
What is the price of the Monjuvi in India?
Monjuvi price in India depends on the product requirement. Request more details by reaching out to our Patient Support Team at (+91) 93157 05373 or help@sansfro.com
Dr Anchal Aryan
Medical counselor
Patient Stories
Word Wide Delivery:
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.